Braveheart Bio, Inc. (BRVE) stock
BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$18.78−0.71 (-3.64%)
Close on Nov 17, 2026Market cap $1.69BP/E –Yield –
Braveheart Bio gross margin
Gross margin is gross profit as a percentage of revenue.
No gross margin figures for Braveheart Bio
Braveheart Bio has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?